Affimed Stock Price, News & Analysis (NASDAQ:AFMD) $0.45 0.00 (0.00%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$0.44▼$0.4750-Day Range$0.32▼$0.5252-Week Range$0.22▼$2.15Volume373,125 shsAverage Volume888,023 shsMarket Capitalization$67.86 millionP/E RatioN/ADividend YieldN/APrice Target$5.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Affimed MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside1,110.4% Upside$5.50 Price TargetShort InterestHealthy1.10% of Shares Sold ShortDividend StrengthN/ASustainability-1.95Upright™ Environmental ScoreNews Sentiment0.93Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.81) to ($0.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.54 out of 5 starsMedical Sector173rd out of 952 stocksPharmaceutical Preparations Industry70th out of 434 stocks 3.4 Analyst's Opinion Consensus RatingAffimed has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.50, Affimed has a forecasted upside of 1,110.4% from its current price of $0.45.Amount of Analyst CoverageAffimed has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.10% of the outstanding shares of Affimed have been sold short.Short Interest Ratio / Days to CoverAffimed has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Affimed has recently decreased by 24.07%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAffimed does not currently pay a dividend.Dividend GrowthAffimed does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAffimed has received a 62.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Cancer medication (L01)" product. See details.Environmental SustainabilityThe Environmental Impact score for Affimed is -1.95. Previous Next 3.3 News and Social Media Coverage News SentimentAffimed has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Affimed this week, compared to 1 article on an average week.Search Interest10 people have searched for AFMD on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Affimed to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Affimed insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.80% of the stock of Affimed is held by insiders.Percentage Held by InstitutionsOnly 30.82% of the stock of Affimed is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Affimed are expected to grow in the coming year, from ($0.81) to ($0.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Affimed is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Affimed is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAffimed has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Affimed Stock (NASDAQ:AFMD)Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.Read More AFMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AFMD Stock News HeadlinesDecember 4, 2023 | finance.yahoo.comAffimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24December 1, 2023 | americanbankingnews.comAffimed (NASDAQ:AFMD) Short Interest UpdateDecember 5, 2023 | Edge On The Street (Ad)The Strategic Gold Play You Haven't Heard AboutExperts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. November 30, 2023 | msn.comAffimed slips as finance chief and science chief departNovember 29, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Affimed (NASDAQ:AFMD)November 20, 2023 | markets.businessinsider.comPromising Investment Potential in Affimed’s Stock: Harnessing Clinical Trials for Lymphoma Treatment and FDA Meeting ResolutionNovember 20, 2023 | finance.yahoo.comAffimed N.V. (NASDAQ:AFMD) Q3 2023 Earnings Call TranscriptNovember 17, 2023 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Affimed (AFMD)December 5, 2023 | Edge On The Street (Ad)The Battery Metal Nobody Told You AboutAccording to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy. Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium "the future of battery tech." November 15, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Syros Pharmaceuticals (SYRS), Affimed (AFMD)November 14, 2023 | finance.yahoo.comAffimed Reports Third Quarter 2023 Financial Results and Highlights Operational ProgressNovember 14, 2023 | benzinga.comRecap: Affimed Q3 EarningsNovember 9, 2023 | finance.yahoo.comAffimed Announces Acimtamig as International Nonproprietary Name for AFM13November 7, 2023 | finance.yahoo.comAffimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023November 7, 2023 | morningstar.comAffimed NV AFMDNovember 3, 2023 | finance.yahoo.comAffimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of CancerNovember 1, 2023 | finance.yahoo.comAffimed to Participate in Upcoming Investor ConferencesOctober 25, 2023 | finance.yahoo.comDown -26.45% in 4 Weeks, Here's Why Affimed N.V. (AFMD) Looks Ripe for a TurnaroundOctober 4, 2023 | finanznachrichten.deAffimed N.V.: Affimed Announces Listing Transfer to Nasdaq Capital MarketsOctober 4, 2023 | finance.yahoo.comAffimed Announces Listing Transfer to Nasdaq Capital MarketsSeptember 27, 2023 | finance.yahoo.comAffimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of CancerSeptember 25, 2023 | benzinga.comWhat 6 Analyst Ratings Have To Say About AffimedSeptember 21, 2023 | finance.yahoo.comAffimed to Present at the Cantor Global Healthcare Conference 2023September 12, 2023 | markets.businessinsider.comAffimed Says FDA Grants Fast Track Designation For AFM13 With AlloNK To Treat R/r Hodgkin LymphomaSeptember 7, 2023 | msn.comCantor Fitzgerald Reiterates Affimed N.V. (AFMD) Overweight RecommendationSeptember 7, 2023 | markets.businessinsider.comExpert Ratings for AffimedAugust 23, 2023 | finance.yahoo.comIs Affimed NV Set to Underperform? Analyzing the Factors Limiting GrowthSee More Headlines Receive AFMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today12/05/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AFMD CUSIPN/A CIK1608390 Webwww.affimed.com Phone496221674360Fax49-6221-653-0777Employees219Year FoundedN/APrice Target and Rating Average Stock Price Target$5.50 High Stock Price Target$7.00 Low Stock Price Target$1.00 Potential Upside/Downside+1,110.4%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-90,610,000.00 Net Margins-638.68% Pretax Margin-641.56% Return on Equity-104.40% Return on Assets-75.85% Debt Debt-to-Equity Ratio0.10 Current Ratio3.70 Quick Ratio3.67 Sales & Book Value Annual Sales$43.58 million Price / Sales1.56 Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book0.35Miscellaneous Outstanding Shares149,340,000Free Float143,664,000Market Cap$67.86 million OptionableOptionable Beta2.05 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Adi Hoess M.D. (Age 62)Ph.D., CEO, MD & Member of Management Board Comp: $818.55kMr. Angus W. Smith (Age 41)CFO & Member of Management Board Comp: $673.91kDr. Wolfgang Fischer (Age 59)MD, COO & Member of Management Board Comp: $638.55kMs. Denise Mueller (Age 53)Chief Business Officer & Member of Management Board Comp: $621.41kDr. Andreas Harstrick M.D. (Age 62)Chief Medical Officer & Member of Management Board Comp: $529.27kDr. Arndt Justus Georg Schottelius M.D. (Age 57)Ph.D., Chief Scientific Officer & Member of Management Board Comp: $641.77kProf. Melvyn LittleFounder & ConsultantMr. Michael Wolf (Age 56)Head of Finance & Administration Mr. Alexander FudukidisHead of Investor Relations & Director of Investor RelationsMary Beth SandinVice President of Marketing & CommunicationsMore ExecutivesKey CompetitorsRallybioNASDAQ:RLYBKaryopharm TherapeuticsNASDAQ:KPTIBriaCell TherapeuticsNASDAQ:BCTXAnnovis BioNYSE:ANVSLifeVantageNASDAQ:LFVNView All CompetitorsInstitutional Ownership683 Capital Management LLCSold 775,000 shares on 11/14/2023Ownership: 5.508%Acadian Asset Management LLCSold 103,448 shares on 11/13/2023Ownership: 0.074%Barclays PLCSold 83,043 shares on 9/21/2023Ownership: 0.050%View All Institutional Transactions AFMD Stock Analysis - Frequently Asked Questions Should I buy or sell Affimed stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AFMD shares. View AFMD analyst ratings or view top-rated stocks. What is Affimed's stock price target for 2024? 8 Wall Street research analysts have issued 1 year price objectives for Affimed's shares. Their AFMD share price targets range from $1.00 to $7.00. On average, they predict the company's share price to reach $5.50 in the next year. This suggests a possible upside of 1,110.4% from the stock's current price. View analysts price targets for AFMD or view top-rated stocks among Wall Street analysts. How have AFMD shares performed in 2023? Affimed's stock was trading at $1.24 on January 1st, 2023. Since then, AFMD shares have decreased by 63.4% and is now trading at $0.4544. View the best growth stocks for 2023 here. Are investors shorting Affimed? Affimed saw a drop in short interest in November. As of November 15th, there was short interest totaling 1,640,000 shares, a drop of 24.1% from the October 31st total of 2,160,000 shares. Based on an average trading volume of 562,700 shares, the days-to-cover ratio is presently 2.9 days. View Affimed's Short Interest. When is Affimed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our AFMD earnings forecast. How were Affimed's earnings last quarter? Affimed (NASDAQ:AFMD) announced its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.01. The biopharmaceutical company earned $10.21 million during the quarter, compared to the consensus estimate of $11.79 million. Affimed had a negative trailing twelve-month return on equity of 104.40% and a negative net margin of 638.68%. During the same quarter in the prior year, the firm earned ($0.08) EPS. What other stocks do shareholders of Affimed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Affimed investors own include Novavax (NVAX), JetBlue Airways (JBLU), SentinelOne (S), American International Group (AIG), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Amarin (AMRN), Rigel Pharmaceuticals (RIGL), Viking Therapeutics (VKTX) and Lipocine (LPCN). Who are Affimed's major shareholders? Affimed's stock is owned by many different retail and institutional investors. Top institutional shareholders include 683 Capital Management LLC (5.51%), Acadian Asset Management LLC (0.07%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Affimed? Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:AFMD) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.